Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an update.
Ondine Biomedical Inc. presented significant findings at the ICPIC 2025 conference, demonstrating the economic and health benefits of its Steriwave nasal photodisinfection technology. The analysis, conducted by the York Health Economics Consortium, showed that using Steriwave could reduce surgical site infections (SSIs) by over 40,000 annually in the UK, resulting in potential cost savings of over £190 million. This innovation not only improves patient outcomes by significantly reducing infection rates compared to existing treatments like Octenisan and mupirocin but also offers substantial economic value by decreasing hospital readmissions and extended stays.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary photodisinfection technology, with applications in nasal decolonization and other medical indications such as chronic sinusitis and ventilator-associated pneumonia.
Average Trading Volume: 388,395
Technical Sentiment Signal: Buy
Current Market Cap: £77.76M
See more insights into OBI stock on TipRanks’ Stock Analysis page.